Description

Retatrutide 20mg — Triple Receptor Agonist, Extended Research Supply

Retatrutide 20mg is the mid-volume format of Brava’s Retatrutide offering — the same compound, sourcing, and third-party verification as the 10mg, in double the quantity.

Retatrutide (LY3437943) is a GLP-1, GIP, and glucagon triple receptor agonist developed by Eli Lilly, currently in Phase III clinical trials. Phase II data showed mean body weight reductions of 24% at 48 weeks — the strongest weight reduction data published for any GLP-1 class compound to date. It’s the most closely watched metabolic research compound in the field right now.

Best For: Metabolic; Body Composition

Category: Metabolic

For Research Use Only (RUO). Not for human or veterinary use. Not a drug. Not intended to diagnose, treat, cure, or prevent any disease.